FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Montserrat Domenech

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Procedures

Co-author Network

Publications

TOP 3
Jaume Trapé; Josep M Badal; Josep Buxó; Sílvia Catot; Montserrat Domenech; Josefina Franquesa; Jesus Montesinos; Maria Sala; Francesc Sant; Anna Arnau
A prognostic score based on clinical factors and biomarkers for advanced non-small cell lung cancer.
Jaume Trapé; Cristina Fígols; Josefina Franquesa; Ana Miguel; Jesús Montesinos; Maria Sala; Montserrat Domenech
Determination of the biological variation of S100β and lactate dehydrogenase in disease-free patients with malignant melanoma.
Joan Carles; Miguel Nogue; Josep M Sole; Palmira Foro; Montserrat Domenech; Marta Suarez; E Gallardo; Darío García; Ferrán Ferrer; Antoni Gelabert-Mas; Javier Gayo; Xavier Fabregat
Phase II study of vinorelbine and estramustine in combination with conformational radiotherapy for patients with high-risk prostate cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Montserrat Domenech (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Jaume Trapé; Josep M Badal; Josep Buxó; Sílvia Catot; Montserrat Domenech; Josefina Franquesa; Jesus Montesinos; Maria Sala; Francesc Sant; Anna Arnau
A prognostic score based on clinical factors and biomarkers for advanced non-small cell lung cancer.
The International journal of biological markers 2012;27(3):e257-62.
2012: Jaume Trapé; Cristina Fígols; Josefina Franquesa; Ana Miguel; Jesús Montesinos; Maria Sala; Montserrat Domenech
Determination of the biological variation of S100β and lactate dehydrogenase in disease-free patients with malignant melanoma.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2012;50(5):927-9.
2010: Joan Carles; Miguel Nogue; Josep M Sole; Palmira Foro; Montserrat Domenech; Marta Suarez; E Gallardo; Darío García; Ferrán Ferrer; Antoni Gelabert-Mas; Javier Gayo; Xavier Fabregat
Phase II study of vinorelbine and estramustine in combination with conformational radiotherapy for patients with high-risk prostate cancer.
International journal of radiation oncology, biology, physics 2010;76(4):1085-91.
2007: Joan Carles; Albert Font; Begoña Mellado; Montserrat Domenech; E Gallardo; José Luis González-Larriba; G Catalan; J Alfaro; A Gonzalez Del Alba; Miquel Nogué; P Lianes; J M Tello
Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study.
British journal of cancer 2007;97(9):1206-10.
2004: Joan Carles; Josep Lloreta; Marta Salido; Albert Font; Marta Suarez; Veronica Baena; Miquel Nogue; Montserrat Domenech; Xavier Fabregat
Her-2/neu expression in prostate cancer: a dynamic process?
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(14):4742-5.
1998: Joan Carles; Montserrat Domenech; Antoni Gelabert-Mas; M Nogue; Josep Tabernero; Angels Arcusa; Inmaculada Guasch; A Miguel; J J Ballesteros; Xavier Fabregat
Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients.
Acta oncologica (Stockholm, Sweden) 1998;37(2):187-91.